[go: up one dir, main page]

SV2009003380A - Agentes terapeuticos - Google Patents

Agentes terapeuticos

Info

Publication number
SV2009003380A
SV2009003380A SV2009003380A SV2009003380A SV2009003380A SV 2009003380 A SV2009003380 A SV 2009003380A SV 2009003380 A SV2009003380 A SV 2009003380A SV 2009003380 A SV2009003380 A SV 2009003380A SV 2009003380 A SV2009003380 A SV 2009003380A
Authority
SV
El Salvador
Prior art keywords
therapeutic agents
dotamin
dopamin
antipsychotics
antipsychotic
Prior art date
Application number
SV2009003380A
Other languages
English (en)
Inventor
Mark T Bilodeau
Nanda Kausik K
B Wesley Trotter
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39540659&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SV2009003380(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of SV2009003380A publication Critical patent/SV2009003380A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Anesthesiology (AREA)
  • Otolaryngology (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)

Abstract

LA PRESENTE INVENCIÓN SE REFIERE A AGENTES TERAPÉUTICOS QUE SON ANTIPSICÓTICOS ATÍPICOS Y QUE SON ÚTILES EN EL TRATAMIENTO DE TRASTORNOS NEUROLÓGICOS Y PSIQUIÁTRICOS ASOCIADOS CON LA DISFUNCIÓN DE LA NEUROTRANSMISIÓN DE DOPAMINA D2 Y SEROTONINA 5-HT2A
SV2009003380A 2007-04-04 2009-09-29 Agentes terapeuticos SV2009003380A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US92175907P 2007-04-04 2007-04-04

Publications (1)

Publication Number Publication Date
SV2009003380A true SV2009003380A (es) 2010-04-13

Family

ID=39540659

Family Applications (1)

Application Number Title Priority Date Filing Date
SV2009003380A SV2009003380A (es) 2007-04-04 2009-09-29 Agentes terapeuticos

Country Status (32)

Country Link
US (3) US8252799B2 (es)
EP (1) EP2144905B1 (es)
JP (2) JP5097265B2 (es)
KR (1) KR101562835B1 (es)
CN (1) CN101675046B (es)
AU (1) AU2008236705B2 (es)
BR (1) BRPI0809492A2 (es)
CA (1) CA2682494C (es)
CO (1) CO6300938A2 (es)
CR (1) CR11047A (es)
CY (1) CY1113649T1 (es)
DK (1) DK2144905T3 (es)
DO (1) DOP2009000232A (es)
EC (1) ECSP099674A (es)
ES (1) ES2398312T3 (es)
GT (1) GT200900258A (es)
HR (1) HRP20130041T8 (es)
IL (1) IL201235A (es)
MA (1) MA31323B1 (es)
MX (1) MX2009010678A (es)
MY (1) MY153868A (es)
NI (1) NI200900175A (es)
NZ (1) NZ580167A (es)
PL (1) PL2144905T3 (es)
PT (1) PT2144905E (es)
RS (1) RS52661B (es)
RU (1) RU2468025C2 (es)
SI (1) SI2144905T1 (es)
SV (1) SV2009003380A (es)
UA (1) UA96015C2 (es)
WO (1) WO2008124030A1 (es)
ZA (1) ZA200906525B (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000032987A (ja) * 1998-07-16 2000-02-02 Dai Ichi Seiyaku Co Ltd Ｄｎａ
ATE431147T1 (de) 2002-08-22 2009-05-15 Dainippon Sumitomo Pharma Co Mittel zur behandlung des integrationsdysfunktionssyndroms
CA2531980C (en) 2003-06-23 2013-09-17 Dainippon Sumitomo Pharma Co., Ltd. Imide derivatives as therapeutic agents for senile dementia
EP1726952A4 (en) 2004-02-20 2008-06-18 Dainippon Sumitomo Pharma Co METHOD FOR IN VIVO SCREENING OF A THERAPEUTIC FOR A MEMORY / LEARNING FUNCTION THROUGH SCHIZOPHRENIA
AU2008236705B2 (en) 2007-04-04 2014-01-23 Merck Sharp & Dohme Corp. Therapeutic agents
US20110124659A1 (en) * 2009-11-17 2011-05-26 Dainippon Sumitomo Pharma Co., Ltd. Cycloalkane derivative
US8258139B2 (en) * 2010-11-08 2012-09-04 Dainippon Sumitomo Pharma Co., Ltd. Method of treatment for mental disorders
PL3156056T3 (pl) 2011-03-18 2024-04-29 Alkermes Pharma Ireland Limited Kompozycje farmaceutyczne zawierające estry sorbitanu
NZ630703A (en) 2012-03-19 2017-02-24 Alkermes Pharma Ireland Ltd Pharmaceutical compositions comprising glycerol esters
JP6333802B2 (ja) 2012-03-19 2018-05-30 アルカームス ファーマ アイルランド リミテッド ベンジルアルコールを含む医薬組成物
JP6471089B2 (ja) 2012-03-19 2019-02-13 アルカームス ファーマ アイルランド リミテッド 脂肪酸エステルを含む医薬組成物
US20130289019A1 (en) * 2012-04-26 2013-10-31 Amazing Grace, Inc. Methods of treating behaviorial and/or mental disorders
AU2013349388B2 (en) 2012-09-19 2018-06-28 Alkermes Pharma Ireland Limited Pharmaceutical compositions having improved storage stability
CN103207246B (zh) * 2012-12-21 2017-10-10 北京万全德众医药生物技术有限公司 一种用液相色谱法分离测定鲁拉西酮及其光学异构体的方法
CN104140421B (zh) * 2013-05-08 2017-04-05 上海医药工业研究院 苯并异噻唑类化合物及在制备抗精神分裂症药物中的应用
RU2688233C2 (ru) 2014-03-20 2019-05-21 Алкермес Фарма Айэленд Лимитед Препараты арипипразола, имеющие повышенные скорости впрыска
CA3208235A1 (en) * 2015-08-31 2017-03-09 Nutramax Laboratories, Inc. Compositions comprising magnolia, phellodendron, theanine and/or whey protein
AU2019230014B2 (en) 2018-03-05 2024-11-28 Alkermes Pharma Ireland Limited Aripiprazole dosing strategy
WO2024091523A1 (en) * 2022-10-24 2024-05-02 2A Biosciences, Inc. Conformationally restricted phenethylamine analogs

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4366172A (en) * 1977-09-29 1982-12-28 The Upjohn Company 4-Amino-cyclohexanols, their pharmaceutical compositions and methods of use
JPH0625181B2 (ja) 1985-03-27 1994-04-06 住友製薬株式会社 新規なイミド誘導体
US5219879A (en) * 1990-03-05 1993-06-15 Du Pont Merck Pharmaceutical Company Heterocyclic steroid compounds
JP2800953B2 (ja) 1990-07-06 1998-09-21 住友製薬株式会社 新規なイミド誘導体
IT1242929B (it) * 1990-11-07 1994-05-18 Nordica Spa Struttura di leva per calzature sportive, particolarmente per scarponi da sci
WO1996014297A1 (en) * 1994-11-04 1996-05-17 Sumitomo Pharmaceuticals Company, Limited Novel lactam derivatives
JP3775823B2 (ja) * 1995-06-09 2006-05-17 大日本住友製薬株式会社 新規なイミド誘導体
AU3789901A (en) * 1999-12-17 2001-06-25 Bristol-Myers Squibb Company Antipsychotic heterocycle compounds
US6599901B1 (en) * 2001-11-19 2003-07-29 Hoffman-La Roche Inc. Pyridone substituted benzothiazole derivatives
CA2531980C (en) 2003-06-23 2013-09-17 Dainippon Sumitomo Pharma Co., Ltd. Imide derivatives as therapeutic agents for senile dementia
DK1652848T3 (da) 2003-07-29 2012-02-27 Dainippon Sumitomo Pharma Co Fremgangsmåde til fremstilling af imidforbindelse
EP1726952A4 (en) 2004-02-20 2008-06-18 Dainippon Sumitomo Pharma Co METHOD FOR IN VIVO SCREENING OF A THERAPEUTIC FOR A MEMORY / LEARNING FUNCTION THROUGH SCHIZOPHRENIA
AU2008236705B2 (en) 2007-04-04 2014-01-23 Merck Sharp & Dohme Corp. Therapeutic agents
US20090076027A1 (en) 2007-09-17 2009-03-19 Protia, Llc Deuterium-enriched lurasidone
US20110003994A1 (en) 2009-07-02 2011-01-06 Dainippon Sumitomo Pharma Co., Ltd. Cycloalkane derivative

Also Published As

Publication number Publication date
US9867821B2 (en) 2018-01-16
US8410111B2 (en) 2013-04-02
KR101562835B1 (ko) 2015-10-23
BRPI0809492A2 (pt) 2014-09-23
US20130178481A1 (en) 2013-07-11
UA96015C2 (en) 2011-09-26
SI2144905T1 (sl) 2013-03-29
KR20090127416A (ko) 2009-12-11
PT2144905E (pt) 2013-02-26
NI200900175A (es) 2010-09-07
HRP20130041T8 (en) 2013-03-31
CA2682494C (en) 2011-10-11
CO6300938A2 (es) 2011-07-21
MA31323B1 (fr) 2010-04-01
EP2144905A1 (en) 2010-01-20
EP2144905B1 (en) 2012-11-28
IL201235A0 (en) 2010-05-31
PL2144905T3 (pl) 2013-04-30
ZA200906525B (en) 2010-04-28
JP5097265B2 (ja) 2012-12-12
CR11047A (es) 2009-10-23
IL201235A (en) 2013-12-31
RS52661B (sr) 2013-06-28
NZ580167A (en) 2012-02-24
CY1113649T1 (el) 2016-10-05
HRP20130041T1 (hr) 2013-02-28
JP2010523567A (ja) 2010-07-15
DOP2009000232A (es) 2016-11-15
AU2008236705A1 (en) 2008-10-16
GT200900258A (es) 2011-10-18
ECSP099674A (es) 2009-11-30
WO2008124030A1 (en) 2008-10-16
CN101675046B (zh) 2013-02-06
JP5686780B2 (ja) 2015-03-18
CN101675046A (zh) 2010-03-17
JP2013028626A (ja) 2013-02-07
HK1134291A1 (en) 2010-04-23
MX2009010678A (es) 2009-10-23
RU2009136592A (ru) 2011-04-20
MY153868A (en) 2015-03-30
US20100105697A1 (en) 2010-04-29
ES2398312T3 (es) 2013-03-15
DK2144905T3 (da) 2013-03-11
RU2468025C2 (ru) 2012-11-27
CA2682494A1 (en) 2008-10-16
US8252799B2 (en) 2012-08-28
AU2008236705B2 (en) 2014-01-23
US20120316181A1 (en) 2012-12-13

Similar Documents

Publication Publication Date Title
SV2009003380A (es) Agentes terapeuticos
CR20110228A (es) Antagonistas del receptor de orexina de isonicotinamida
CO6351717A2 (es) Tripiridil carboxamida como antagonista del receptor de orexina
HN2007015177A (es) Derivados de triazolopirazina
UY33865A (es) Derivados Heterocíclicos Novedosos y su Uso en el Tratamiento de Trastornos Neurológicos
ME01532B (me) Jedinjenja
GT201200016A (es) Derivados de oxazina y su uso como inhibidores de bace para el tratamiento de trastornos neurológicos
NI200900100A (es) Antagonistas de receptor de orexina de diazepan sustituido
PL2049132T3 (pl) Nowe środki do leczenia zaburzeń związanych z osłabionym neuroprzekaźnictwem
HN2008000974A (es) Derivados de bencimidazol
AR072699A1 (es) Antagonistas especificos del receptor 4 del factor de crecimiento de los fi-broblastos (fgf-r4)
EA201001372A1 (ru) Формы рифаксимина и их применение
HN2011003139A (es) Antagonistas de trayectoria de erizo de ftalazina disustituida
DE602007008434D1 (de) Rezeptoren
NI200800314A (es) Compuestos de amidas de piridil sustituidos como moduladores del receptor de histamina h3
CR11818A (es) Derivados de triazol utiles para el tratamiento de enfermedades
EP2400938A4 (en) OXYGEN PRODUCTION BANDAGE WITH OXYGEN EXTRACTION SOURCE
GT201100336A (es) Sulfonamidas heterocíclicas, usos y composiciones farmacéuticas de las mismas
CL2009000119A1 (es) Compuestos derivados de amino-bencimidazoles sustituidos; composicion farmaceutica; y su uso en el tratamiento del alzheimer.
ECSP11011021A (es) Antagonistas de la via hedgehog de ftalazina disustituida
CR11529A (es) Compuestos de cicloalquiloxi y heterocicloalquilopiridina como moduladores del receptor de h3 de histamina
BRPI0821026A2 (pt) Derivados de alfa-minoamidas úteis no tratamento de transtornos psiquiátricos
UY31840A (es) Pirrolidin amidas sustituidas como moduladores del receptor histamina h3
CL2012001606A1 (es) Compuestos derivados de tiazoles bicíclicos como moduladores alostéricos de receptores mglur5; composición farmacéutica que los comprende; procedimiento de preparación de la composición farmacéutica; combinación farmacéutica; y uso del compuesto en la prevención, tratamiento o profilaxis de trastornos neurológicos o psiquiátricos.
NZ598247A (en) Compositions and methods for treating parkinson’s disease